Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC
Exosomes detection for the prediction of the efficacy and adverse reactions of Anlotinib in patients with advanced NSCLC
Non-Small Cell Lung Cancer
DRUG: Anlotinib
PD, Progressive disease (PD) after anlotinib administration, at the time of 2 months (2 cycles after treatment)|SD, Stable disease (SD) after anlotinib administration, at the time of 2 months (2 cycles after treatment)
Severe adverse reaction group, Severe adverse reaction group after anlotinib administration, at the time of 2 months (2 cycles after treatment)|Adverse reaction non-serious group, Adverse reaction non-serious group after anlotinib administration, at the time of 2 months (2 cycles after treatment)
Explore blood exosomal miRNA as a biomarker for predicting the efficacy or risk of serious adverse reactions in patients with advanced lung adenocarcinoma (or lung squamous cell carcinoma) after anlotinib treatment.